MayTech Global Investments LLC Buys 123,200 Shares of Novo Nordisk A/S (NYSE:NVO)

MayTech Global Investments LLC raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 48.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 377,752 shares of the company’s stock after buying an additional 123,200 shares during the quarter. Novo Nordisk A/S comprises about 3.8% of MayTech Global Investments LLC’s investment portfolio, making the stock its 12th largest holding. MayTech Global Investments LLC’s holdings in Novo Nordisk A/S were worth $32,494,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Novo Nordisk A/S by 3.2% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 95,080 shares of the company’s stock worth $8,179,000 after buying an additional 2,920 shares during the period. Mmbg Investment Advisors CO. acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $1,520,000. LRI Investments LLC raised its position in Novo Nordisk A/S by 1.4% during the 4th quarter. LRI Investments LLC now owns 13,060 shares of the company’s stock worth $1,123,000 after buying an additional 176 shares during the last quarter. Lighthouse Investment Partners LLC boosted its holdings in shares of Novo Nordisk A/S by 148.4% in the 4th quarter. Lighthouse Investment Partners LLC now owns 38,500 shares of the company’s stock valued at $3,312,000 after acquiring an additional 23,000 shares during the last quarter. Finally, JARISLOWSKY FRASER Ltd increased its stake in shares of Novo Nordisk A/S by 5.4% in the fourth quarter. JARISLOWSKY FRASER Ltd now owns 77,441 shares of the company’s stock worth $6,661,000 after acquiring an additional 3,944 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $67.70 on Tuesday. The firm has a market cap of $303.79 billion, a PE ratio of 20.58, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $148.15. The business’s fifty day simple moving average is $68.75 and its 200-day simple moving average is $85.51. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. The firm had revenue of $11.87 billion for the quarter, compared to analyst estimates of $79.17 billion. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analyst Ratings Changes

NVO has been the topic of several analyst reports. Guggenheim downgraded Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 17th. BMO Capital Markets reaffirmed a “market perform” rating and set a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Dbs Bank downgraded shares of Novo Nordisk A/S to a “sell” rating in a research report on Friday, April 25th. Finally, StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and a consensus price target of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.